FBDIX: Franklin Biotechnology Discovery A

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Fixed income news, reports, video and more.

Municipal bonds news, reports, video and more.

Practice management news, reports, video and more.

Portfolio management news, reports, video and more.

Retirement news, reports, video and more.

Learn from industry thought leaders and expert market participants.

Deepen your understanding of Responsible Investing and learn how it can potentially help you build a more successful practice.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

FBDIX Franklin Biotechnology Discovery A


Profile

FBDIX - Profile

Vitals

  • YTD Return 18.1%
  • 3 Yr Annualized Return 3.3%
  • 5 Yr Annualized Return -1.9%
  • Net Assets $1.38 B
  • Holdings in Top 10 46.9%

52 WEEK LOW AND HIGH

$178.22
$112.63
$184.88

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.03%

SALES FEES

  • Front Load 5.50%
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 32.92%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) $1,000
  • IRA $250

Fund Classification


Distributions

  • YTD Total Return 18.1%
  • 3 Yr Annualized Total Return 4.2%
  • 5 Yr Annualized Total Return 1.2%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.49%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Franklin Biotechnology Discovery Fund
  • Fund Family Name
    Franklin Templeton Investments
  • Inception Date
    Sep 15, 1997
  • Shares Outstanding
    6408134
  • Share Class
    A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Evan McCulloch

Fund Description

Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.


Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.


Categories

Performance

FBDIX - Performance

Return Ranking - Trailing

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
YTD 18.1% -9.9% 23.9% 17.05%
1 Yr 26.6% 2.4% 41.8% 26.19%
3 Yr 3.3%* -13.2% 18.7% 64.55%
5 Yr -1.9%* -11.1% 13.1% 74.76%
10 Yr 11.1%* -1.7% 16.9% 32.14%

* Annualized

Return Ranking - Calendar

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
2019 23.3% 5.7% 55.4% 26.72%
2018 -18.6% -25.3% 21.5% 90.91%
2017 16.0% -10.8% 43.9% 50.93%
2016 -20.7% -31.6% 6.9% 77.14%
2015 -3.0% -20.4% 13.8% 60.00%

Total Return Ranking - Trailing

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
YTD 18.1% -9.9% 23.9% 17.05%
1 Yr 26.6% 2.4% 41.8% 26.19%
3 Yr 4.2%* -13.2% 21.7% 64.55%
5 Yr 1.2%* -11.1% 17.9% 59.22%
10 Yr 15.7%* -1.7% 19.1% 28.57%

* Annualized

Total Return Ranking - Calendar

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
2019 23.3% 5.7% 55.4% 26.72%
2018 -18.6% -25.3% 22.2% 91.82%
2017 18.8% -10.8% 45.8% 56.48%
2016 -17.1% -26.4% 8.7% 74.29%
2015 5.7% -16.6% 15.2% 56.00%

NAV & Total Return History


Holdings

FBDIX - Holdings

Concentration Analysis

FBDIX Category Low Category High FBDIX % Rank
Net Assets 1.38 B 2.42 M 49.6 B 45.19%
Number of Holdings 91 27 433 48.89%
Net Assets in Top 10 647 M 784 K 18.8 B 31.11%
Weighting of Top 10 46.86% 23.2% 75.9% 17.78%

Top 10 Holdings

  1. Regeneron Pharmaceuticals Inc 6.72%
  2. Vertex Pharmaceuticals Inc 6.63%
  3. Amgen Inc 5.65%
  4. Illumina Inc 4.87%
  5. Novavax Inc 4.62%
  6. Gilead Sciences Inc 4.04%
  7. GW Pharmaceuticals PLC ADR 3.90%
  8. Biogen Inc 3.76%
  9. Immunomedics Inc 3.68%
  10. Iovance Biotherapeutics Inc 2.99%

Asset Allocation

Weighting Return Low Return High FBDIX % Rank
Stocks
94.07% 61.47% 100.23% 88.15%
Cash
4.68% -0.23% 32.46% 11.11%
Other
1.26% -3.74% 6.07% 15.56%
Preferred Stocks
0.00% 0.00% 6.63% 34.81%
Convertible Bonds
0.00% 0.00% 0.00% 19.26%
Bonds
0.00% 0.00% 16.11% 22.22%

Stock Sector Breakdown

Weighting Return Low Return High FBDIX % Rank
Healthcare
99.24% 61.81% 100.00% 54.81%
Financial Services
0.76% 0.00% 2.43% 10.37%
Utilities
0.00% 0.00% 0.00% 19.26%
Technology
0.00% 0.00% 20.28% 28.15%
Real Estate
0.00% 0.00% 6.03% 23.70%
Industrials
0.00% 0.00% 6.39% 22.22%
Energy
0.00% 0.00% 0.00% 19.26%
Communication Services
0.00% 0.00% 3.18% 22.22%
Consumer Defense
0.00% 0.00% 34.31% 26.67%
Consumer Cyclical
0.00% 0.00% 1.12% 28.89%
Basic Materials
0.00% 0.00% 2.61% 40.00%

Stock Geographic Breakdown

Weighting Return Low Return High FBDIX % Rank
US
82.52% 47.91% 99.43% 30.37%
Non US
11.55% 0.00% 43.93% 74.81%

Expenses

FBDIX - Expenses

Operational Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.03% 0.10% 25.14% 68.18%
Management Fee 0.60% 0.00% 1.25% 19.26%
12b-1 Fee 0.25% 0.00% 1.00% 20.83%
Administrative Fee 0.15% 0.03% 0.40% 51.16%

Sales Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load 5.50% 3.50% 5.75% 56.00%
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 32.92% 0.70% 248.00% 32.06%

Distributions

FBDIX - Distributions

Dividend Yield Analysis

FBDIX Category Low Category High FBDIX % Rank
Dividend Yield 0.00% 0.00% 0.05% 22.96%

Dividend Distribution Analysis

FBDIX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Quarterly Annually

Net Income Ratio Analysis

FBDIX Category Low Category High FBDIX % Rank
Net Income Ratio -0.49% -2.53% 2.12% 75.19%

Capital Gain Distribution Analysis

FBDIX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

FBDIX - Fund Manager Analysis

Managers

Evan McCulloch


Start Date

Tenure

Tenure Rank

Sep 15, 1997

22.98

23.0%

Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.

Wendy Lam


Start Date

Tenure

Tenure Rank

Sep 01, 2018

2.0

2.0%

Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co.

Akiva Felt


Start Date

Tenure

Tenure Rank

Jan 27, 2020

0.59

0.6%

Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.01 22.98 8.69 20.35